Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer painLynn R. Webster, Eric Carter, Gordon Irving et al.|Pain|2008Cited by 144
Effects of concurrent intravenous morphine sulfate and naltrexone hydrochloride on end-tidal carbon dioxideVeeraindar Goli, Eric Carter, Lynn R. Webster et al.|Harm Reduction Journal|2012Cited by 5